Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 214,800 shares, an increase of 214.5% from the November 30th total of 68,300 shares. Based on an average trading volume of 461,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 4.6% of the company’s shares are short sold.

Entero Therapeutics Stock Performance

Shares of ENTO stock traded down $0.03 during trading hours on Friday, reaching $0.60. The company had a trading volume of 100,566 shares, compared to its average volume of 354,361. Entero Therapeutics has a 1-year low of $0.19 and a 1-year high of $9.35. The company has a 50 day moving average of $0.59 and a 200 day moving average of $0.70.

Entero Therapeutics (NASDAQ:ENTO) last issued its quarterly earnings data on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Equities research analysts forecast that Entero Therapeutics will post -1.13 EPS for the current year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.